BRIO's unique relationship with a network of labs across the country allows it to offer customers a three-day or less turnaround for delivering COVID-19 test results, even as delivery times have lagged throughout the country amid new coronavirus case spikes. Its network of lab partners have historically been confined to customers in close geographic proximity, but BRIO's platform effectively matches corporate customer needs with labs who can best meet capacity and demand. BRIO's platform allows employers to measure both active COVID-19 infections through FDA Emergency Use Authorized-PCR testing, as well as previous exposure to the virus through industry-leading serological testing, which measures both IgM and IgG antibodies in quantitative formats.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/05/20 | $1,900,000 | Seed |
Castor Ventures John Capodilupo Nimble Ventures One Way Ventures  TechStars | undisclosed |
